奈达铂联合多西他赛同步放化疗治疗老年局部晚期非小细胞肺癌临床疗效观察  

Observation of clinical efficacy of nedaplatin plus docetaxel with concurrent radiotherapy in the treatment of elderly patients with locally advanced non-small cell lung cancer

作　　者：房丽[1] 王红阳[2] 王轶楠[1] 马守东[1] 王玲玲[1] 刘卫东[1] 郑海荣[2] 

机构地区：[1]唐山市人民医院放化疗科,河北唐山063000 [2]河北联合大学医学部呼吸内科,河北唐山063000

出　　处：《临床肺科杂志》2014年第8期1480-1484,共5页Journal of Clinical Pulmonary Medicine

基　　金：河北省中医药管理局;中医药;中西医结合科研计划课题(No 2009229)

摘　　要：目的评价奈达铂联合多西他赛同步放化疗治疗老年局部晚期非小细胞肺癌（NSCLC）的近期临床疗效及毒副反应。方法 60例诊断明确的老年局部晚期NSCLC患者随机分为两组,均接受三维适形放疗,照射剂量60～66 Gy;并每周一次同步化疗,方案分别为奈达铂（NDP组）或顺铂（DDP组）联合多西他赛。奈达铂用量为20～25 mg/m2,顺铂为20～25 mg/m2;多西他赛为30 mg/m2;观察两组近期疗效及毒副反应。结果 NDP组和DDP组总有效率均为70.0%;两组中位生存时间分别为17.5个月和16.8个月;差异无统计学意义（P＆gt;0.05）;但NDP组骨髓抑制及胃肠道反应发生率明显低于DDP组（P〈0.05）。结论奈达铂联合多西他赛同步放化疗治疗老年局部晚期NSCLC有效率不低于顺铂双药方案,且胃肠道反应显著减低,患者耐受性好,更易让患者接受。Objective To evaluate the clinical efficacy and toxicity of of nedaplatin plus docetaxel with concurrent radiotherapy in the treatment of elderly patients with locally advancedd NSCLC. Methods 60 elderly NSCLC patients at stage Ⅲ were divided into the NDP group（ n = 30） and the DDP group（ n = 30）. All patients were treated with radiotherapy and DT 60 ～ 66Gy. The NDP group was given NDP 20 ～ 25mg /m2,and the DDP group was given DDP 20 ～ 25 mg /m2. All patients were additionally treated with docetaxel 30mg /m2. Results The total response rate of the NDP and DDP groups were both 70. 0%,and MST of the two groups were 17. 5 months and16. 8 months respectively（ P〈0. 05）. The major toxic reaction of the NDP group was obviously lower than that in the DDP group. Conclusion Nedaplatin plus docetaxel with concurrent radiotherapy is effective for elderly patients with NSCLC at stage Ⅲ,which can improve the quality of life and prolong the survival time.

关 键 词：非小细胞肺癌 同步放化疗 奈达铂 多西他赛 

分 类 号：R734.2[医药卫生—肿瘤]